MA28653B1 - Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation - Google Patents

Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation

Info

Publication number
MA28653B1
MA28653B1 MA29515A MA29515A MA28653B1 MA 28653 B1 MA28653 B1 MA 28653B1 MA 29515 A MA29515 A MA 29515A MA 29515 A MA29515 A MA 29515A MA 28653 B1 MA28653 B1 MA 28653B1
Authority
MA
Morocco
Prior art keywords
compounds
pyrazoles
new
products containing
medicinal products
Prior art date
Application number
MA29515A
Other languages
English (en)
Inventor
Harm Brummerhop
Wendelin Frick
Heiner Glombik
Oliver Plettenburg
Martin Bickel
Hubert Heuer
Stefan Theis
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA28653B1 publication Critical patent/MA28653B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

Nouveaux dérivés fluoroglycosidiques des pyrazoles, les médicaments contenant ces composés et leur utilisation. L'invention concerne des dérivés fluoroglycosidiques substitués des pyrazoles de formule (I), dans laquelle les radicaux ont les significations indiquées, les sels physiologiquement compatibles de ceux-ci, et une méthode de production de ceux-ci. Les composés conviennent par exemple en tant qu'antidiabétiques.
MA29515A 2004-06-11 2006-12-05 Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation MA28653B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004028241A DE102004028241B4 (de) 2004-06-11 2004-06-11 Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel

Publications (1)

Publication Number Publication Date
MA28653B1 true MA28653B1 (fr) 2007-06-01

Family

ID=35355753

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29515A MA28653B1 (fr) 2004-06-11 2006-12-05 Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation

Country Status (33)

Country Link
US (1) US7820804B2 (fr)
EP (1) EP1758914B1 (fr)
JP (1) JP4996464B2 (fr)
CN (1) CN100582116C (fr)
AR (1) AR049393A1 (fr)
AU (1) AU2005252329B2 (fr)
BR (1) BRPI0510770A (fr)
CA (1) CA2570042C (fr)
CR (1) CR8773A (fr)
CY (1) CY1107426T1 (fr)
DE (2) DE102004028241B4 (fr)
DK (1) DK1758914T3 (fr)
EC (1) ECSP067054A (fr)
ES (1) ES2296180T3 (fr)
HR (1) HRP20080023T3 (fr)
IL (1) IL179757A (fr)
MA (1) MA28653B1 (fr)
MX (1) MXPA06013513A (fr)
MY (1) MY143565A (fr)
NO (1) NO20070176L (fr)
NZ (1) NZ551948A (fr)
PE (1) PE20060297A1 (fr)
PL (1) PL1758914T3 (fr)
PT (1) PT1758914E (fr)
RS (1) RS50541B (fr)
RU (1) RU2370499C2 (fr)
SI (1) SI1758914T1 (fr)
TN (1) TNSN06409A1 (fr)
TW (1) TWI382030B (fr)
UA (1) UA89787C2 (fr)
UY (1) UY28955A1 (fr)
WO (1) WO2005121161A1 (fr)
ZA (1) ZA200608832B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2076503B1 (fr) 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd Composé de c-phényle-glycitol pour le traitement du diabète
US8115017B2 (en) * 2006-06-29 2012-02-14 Taisho Pharmaceutical Co., Ltd C-phenyl 1-thioglucitol compound
EP2061767B1 (fr) 2006-08-08 2014-12-17 Sanofi Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
DE102006053637B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2008072726A1 (fr) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. Dérivé de 1-phényl 1-thio-d-glucitol
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
JP5272395B2 (ja) * 2007-12-12 2013-08-28 セントラル硝子株式会社 ４−デオキシ−４−フルオロ−ｄ−グルコース誘導体の製造方法
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
AU2009286380B2 (en) * 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
AR075582A1 (es) 2009-02-23 2011-04-20 Taisho Pharmaceutical Co Ltd Compuestos de 4- isopropilfenilglucitol
KR20120060207A (ko) * 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2298782A1 (fr) * 2009-08-26 2011-03-23 Sanofi-Aventis Procédé de synthèse de dérivé de type pyrazole glucoside
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
RS53827B1 (sr) 2009-11-02 2015-06-30 Pfizer Inc. Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
EP2498759B1 (fr) 2009-11-13 2018-08-01 AstraZeneca AB Formulations pour comprimés à libération immédiate
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
WO2011060255A1 (fr) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Formulations de metformine a masse reduite
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2607360B1 (fr) 2010-08-20 2015-08-19 Taisho Pharmaceutical Co., Ltd. Dérivé du 4-isopropyl-6-méthoxyphényl glucitol
TW201219414A (en) 2010-08-20 2012-05-16 Taisho Pharmaceutical Co Ltd Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
EP2611442B1 (fr) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Formulations de médicament au moyen d'antioxydants hydrosolubles
BR112013019026A2 (pt) 2011-02-01 2016-10-04 Astrazeneca Uk Ltd formulações farmacêuticas incluindo um composto amina
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8614195B2 (en) * 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
MY176162A (en) 2013-02-04 2020-07-24 Taisho Pharmaceutical Co Ltd Prophylactic or therapeutic drug for constipation
EP2774619B1 (fr) 2013-03-04 2016-05-18 BioActive Food GmbH Composition pour le traitement de pathologies hyperglycémiques
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
EP2944311A1 (fr) 2014-05-16 2015-11-18 BioActive Food GmbH Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
EP3778593A4 (fr) * 2018-04-04 2021-12-22 Japan Tobacco Inc. Composé de pyrazole substitué par hétéroaryle et son utilisation médicinale
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CA3121202A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composes pyrrole et pyrazole et leurs procedes d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT850948E (pt) * 1996-12-26 2002-08-30 Tanabe Seiyaku Co Derivados propiofenona e processo para a preparacao dos mesmos
KR100591585B1 (ko) * 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
ES2337127T3 (es) * 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
AU2002240336A1 (en) * 2001-02-14 2002-08-28 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
WO2003020737A1 (fr) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company Inhibiteurs de sglt2 contenant du glucoside de o-pyrazole et methode d'utilisation
RU2356906C2 (ru) * 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) * 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
US7576063B2 (en) * 2002-10-04 2009-08-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
US20060035844A1 (en) * 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2529878C (fr) * 2003-06-20 2012-11-20 Kissei Pharmaceutical Co., Ltd. Derive de pyrazole, composition de medicaments contenant ledit derive et intermediaire de production associe

Also Published As

Publication number Publication date
CY1107426T1 (el) 2012-12-19
CA2570042C (fr) 2013-01-15
JP2008501745A (ja) 2008-01-24
ECSP067054A (es) 2007-01-26
WO2005121161A1 (fr) 2005-12-22
DE502005002056D1 (de) 2008-01-03
UY28955A1 (es) 2006-01-31
RU2007101154A (ru) 2008-07-20
EP1758914A1 (fr) 2007-03-07
MXPA06013513A (es) 2007-03-01
DE102004028241A1 (de) 2006-01-05
TW200610527A (en) 2006-04-01
CA2570042A1 (fr) 2005-12-22
IL179757A (en) 2010-12-30
BRPI0510770A (pt) 2007-11-20
IL179757A0 (en) 2007-05-15
DE102004028241B4 (de) 2007-09-13
UA89787C2 (ru) 2010-03-10
PT1758914E (pt) 2008-01-31
EP1758914B1 (fr) 2007-11-21
NZ551948A (en) 2010-04-30
JP4996464B2 (ja) 2012-08-08
MY143565A (en) 2011-05-31
CR8773A (es) 2008-02-28
RS50541B (sr) 2010-05-07
ZA200608832B (en) 2008-05-28
PL1758914T3 (pl) 2008-04-30
CN100582116C (zh) 2010-01-20
US7820804B2 (en) 2010-10-26
AU2005252329B2 (en) 2011-02-10
SI1758914T1 (sl) 2008-04-30
NO20070176L (no) 2007-03-09
HRP20080023T3 (en) 2008-06-30
AU2005252329A1 (en) 2005-12-22
PE20060297A1 (es) 2006-05-25
US20070197623A1 (en) 2007-08-23
CN1964984A (zh) 2007-05-16
TNSN06409A1 (en) 2008-02-22
TWI382030B (zh) 2013-01-11
DK1758914T3 (da) 2008-03-17
RU2370499C2 (ru) 2009-10-20
ES2296180T3 (es) 2008-04-16
HK1100411A1 (zh) 2007-09-21
AR049393A1 (es) 2006-07-26

Similar Documents

Publication Publication Date Title
MA28653B1 (fr) Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation
JP2617546B2 (ja) ３‐〔４（１‐置換‐４‐ピペラジニル）ブチル〕‐４‐チアゾリジノンおよびその製法
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
MA27735A1 (fr) Heterocycles de n-aryle substitues, procede pour leur preparation et leur utilisation en tant que medicaments
TNSN06200A1 (fr) Derives de quinoleine nouveaux
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
TN2009000327A1 (fr) Procede pour la preparation d'un derive de benzimidazole
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
SI20473A (sl) Tienilazolilalkoksietanamini, njihova priprava in njihova uporaba kot zdravila
CN113801073B (zh) 14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
CA2944211C (fr) Compositions et methodes pour traiter des maladies neurodegeneratives
TNSN00250A1 (fr) Composes nouveaux inhibiteurs de pcp, procede pour leur preparation et compositions les contenant
Woodley et al. Enantioselective synthesis and profiling of potent, nonlinear analogues of antimalarial tetraoxanes E209 and N205
US20240101584A1 (en) Targeted delivery of 1,2,4,5 tetraoxane compounds and their uses
ES2494765T3 (es) Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión
MA27195A1 (fr) Derives d'acyl-3 -carboxyphenyluree, procedes pour les preparer et leur utilisation.
FR2859208B1 (fr) Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI0413101A (pt) compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos
MA27963A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
UA90290C2 (ru) Производные спирокеталов и их применение в качестве лекарственного средства против диабета